BUZZ-Novo falls on U.S. President Trump's lower Ozempic price comments
Shares of Novo Nordisk fell approximately 5% following U.S. President Donald Trump's comments about lowering the price of Ozempic, the company's leading weight-loss drug. Analyst Per Hansen noted that there was nothing new in Trump's statements and confirmed that price negotiations are ongoing, with results expected in the coming months. If the losses persist, it could mark Novo's worst trading day since August.
Shares in Novo Nordisk (NOVOb.CO) fall around 5% after U.S. President Donald Trump on Thursday said the price of Novo’s best-selling weight-loss drug would be lowered and that negotiations over price changes would be swift
Nordnet analyst Per Hansen says “there is nothing new in the statements” and that prices will be lower
Novo’s Ozempic is one of the drugs that has been chosen for price negotiations, with Hansen saying the “price negotiations are still ongoing, and the results will probably be known in the coming months”
If losses hold, Novo shares will track worst day since August
